India's Top 10 Pharma Companies
1. Sun Pharma
Net Profit (in Rs. Cr) = 1927.98
It is an Indian global pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. When the company began in 1983, Sun Pharma introduced the concept of speciality marketing in the Indian pharma industry. In 2007, Sun Pharma demerged its R&D arm and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. In the US, a key area for the company, it has taken both organic and in-organic (acquisition of Caraco Pharma Labs and Taro Pharmaceuticals) routes to grow.
2. Cipla
Net Profit (in Rs. Cr) = 1123.96
It is an Indian pharmaceutical company, probably best-known outside its home country for pioneering the manufacture of low-cost anti-AIDS drugs for HIV-positive patients in developing countries. In May 2012, Cipla made headlines worldwide by reducing prices on several cancer drugs which were previously priced so high that a vast majority of the world's population could not afford them. Cipla received the Thomson Reuters India Innovation Award in 2012.
3. Dr. Reddy’s Laboratories
Net Profit (in Rs. Cr) = 912.40
Dr. Reddy’s began as an API manufacturer in 1984, producing high-quality APIs to the Indian as well as the international markets. Through their three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, Custom Pharmaceutical Services, Generics, Biosimilars, Differentiated Formulations and New Chemical Entities (NCEs). Their major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.
4. Lupin Limited
Net Profit (in Rs. Cr) = 804.37
Headquartered in Mumbai, India, Lupin Limited today is a trans-national pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. Lupin first came into the limelight when it became one of the world's largest manufacturers of Tuberculosis drugs. Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction.
5. Cadila Healthcare
Net Profit (in Rs. Cr) = 657.50
Cadila Healthcare is an Indian pharmaceutical company head quartered at Ahmedabad. It develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. To its credit, Cadila is the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. A lesser-known fact about the company is that it also participates in public-private partnerships for developing diagnostic, preventive and curative pharmaceutical and diagnostic products.
6. JB Chemicals
Net Profit (in Rs. Cr) = 642.70
Established in 1976 and headquartered in Mumbai, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organization with a focus on supplying affordable, quality products both in India and international markets, JBCPL today exports to over 30 countries across the world and earns more than half its revenue from its international business. JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectables (vials, ampoules, and form fill seal), creams & ointments, lozenges, herbal liquids and capsules.
7. Divis Labs
Net Profit (in Rs. Cr) = 545.97
Established in the year 1990 with R&D as its prime focus, Divis Laboratories mainly develops new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. Divis Laboratories also boasts of five years of experience, expertise and a proven track-record of helping many companies with its turn-key and consulting strengths. It established its first manufacturing facility in 1995. Divis manufacture API's for the Generics. It is actively involved in developing alternate, patent non-infringing processes for APIs, for the inventors to manage late life cycle and leading generic drug manufacturers.
8. GlaxoSmithKline Pharmaceuticals Ltd
Net Profit (in Rs. Cr) = 430.60
It is an Indian subsidiary of GlaxoSmithKline plc, one of the world's leading research based pharmaceutical and healthcare companies. It is one of the oldest pharmaceuticals companies in India. Its product portfolio includes prescription medicines and vaccines. It was founded in November 1924 in India under the name of H.J.Foster & Co. Limited as an agency house for distributing baby food Glaxo, Joseph Nathan & Co. In 1950, it changed its name to Glaxo Laboratories (I) Ltd.
9. Torrent Pharmaceuticals Ltd.
Net Profit (in Rs. Cr) = 311.25
Torrent Pharmaceuticals Ltd., the flagship company of the Torrent Group, is based out of Ahmedabad. It was promoted by U. N. Mehta initially as Trinity Laboratories Ltd. which was later renamed to Torrent Pharmaceuticals Ltd. Torrent Pharmaceuticals acquired Heumann GmbH, a Pfizer group company in 2005. Torrent Pharmaceuticals operates in more than 50 countries with over 1000 product registrations globally. The company's key areas are Formulations, API, Drug Discovery, Marketing and Sales of Drugs.
10. Ipca Labs
Net Profit (in Rs. Cr) = 280.17
It is an international pharmaceutical company based in Mumbai, India. It was founded by group of businessmen and medical professionals in 1949. In 1975, the management of the company was taken over by Amitabh Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C. Godha. The main activities of company are to produce and market pharmaceuticals and drugs. The various products of the company include formulations, drug intermediates, and active pharmaceutical ingredients (API). In 2004, Ipca was selected by Forbes, as one among the first 200 'Best under a Billion Company' in Asia for the second consecutive year.
